Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioNTech Revenues Triple in the First Quarter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

BioNTech Revenues Triple in the First Quarter

Increase in commercial revenues from the supply and sales of the company's COVID-19 vaccine more than triple earnings.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech
1Q Revenues: €6.4 billion (up from €2.0 billion 1Q21)
1Q Earnings: €3.7 billion (up from €1.1 billion 1Q21)
Comments: Growth in the quarter due to increased commercial revenues from the supply and sales of the company’s COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. During the quarter, BioNTech’s commercial revenues included €4.6 billion gross profit share (€1.5 billion gross profit share and €247.2 million in sales milestones during 1Q21). 
 
BioNTech also recognized €1.2 billion of direct COVID-19 vaccine sales to customers in BioNTech’s territory, Germany and Turkey, as well as €603.2 million sales of products manufactured by BioNTech for its collaboration partners (€199.8 million and €63.9 million, respectively during the comparative prior year period).
 
R&D expenses were €285.8 million in the quarter, compared to €216.2 million in 1Q21. The increase was mainly due to recognizing costs related to the production of pre-launch Omicron vaccine products as R&D expenses in the period incurred and an increase in headcount. The increase was partly offset by lower R&D expenses related to the Company’s COVID-19 vaccine program as compared to 1Q21.
 
Pipeline Update:
First-in-class CAR-T program targeting CLDN-6 (BNT211) in solid tumors showed manageable safety profile and signs of clinical activity; preliminary Phase 1/2 data. Continued pipeline expansion to 16 clinical stage oncology programs in 20 ongoing clinical trials.

 
Pfizer and BioNTech are still pursuing authorization for U.S. Emergency Use for a COVID-19 vaccine booster dose in children 5 through 11 years of age.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters